Skip to main content

Advertisement

SpringerLink
Log in

Quantification of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia: Comparison Between HPLC–UV and LC–MS/MS

  • Published:
International Journal of Peptide Research and Therapeutics Aims and scope Submit manuscript

Abstract

Measurement of imatinib plasma concentration can be useful to evaluate patient adherence to daily oral therapy, potential drug–drug interaction, treatment efficacy, and severe drug-related adverse events. The aim of this study was to correlate the two different blood level test methods, HPLC–UV and LC–MS/MS. We analyzed 162 plasma samples from patients treated with imatinib. We estimated the correlation between the two analytical methods on total data set and on five sets of patients grouped into different categories based on the drug-dose therapy. Finally, imatinib quantification was correlated with genetic data on the molecular response in monitoring follow-up of CML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

CML:

Chronic myeloid leukemia

CCR:

Cytogenetic response

MMR:

Major molecular response

LC–MS/MS:

Liquid chromatography coupled with tandem mass spectrometry

HPLC–UV:

High performance liquid chromatography coupled with UV detection

BLT:

Blood level test

SRM:

Selected reaction monitoring

MR:

Molecular response

References

  • Awidi A, Salem II, Najib N, Mefleh R, Tarawneh B (2010) Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods’ comparison. Leuk Res 34:714–717

    Article  PubMed  CAS  Google Scholar 

  • Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006) European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809–1820

    Article  PubMed  CAS  Google Scholar 

  • Bakhtiar R, Khemani L, Hayes M, Bedman T, Tse F (2002) Quantification of the anti-leukemia drug STI571 and its metabolite (CGP 74588) in monkey plasma using a semi automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 28:1183–1194

    Article  PubMed  CAS  Google Scholar 

  • Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F (2007) High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 768:325–340

    Article  Google Scholar 

  • Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310

    Article  PubMed  CAS  Google Scholar 

  • Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112:3330–3338

    Article  PubMed  CAS  Google Scholar 

  • Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration (2001)

  • Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690–698

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    Article  PubMed  CAS  Google Scholar 

  • Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe against Cancer Program. Leukemia 17:2318–2357

    Article  PubMed  CAS  Google Scholar 

  • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880

    Article  PubMed  CAS  Google Scholar 

  • Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y (2008) IRIS (international randomized interferon vs STI571) Study Group, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–4028

    Article  PubMed  CAS  Google Scholar 

  • Lee MS, Kerns EH (1999) LC/MS applications in drug development. Mass Spectrom Rev 18:187–279

    Article  PubMed  CAS  Google Scholar 

  • Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368–2373

    Article  PubMed  CAS  Google Scholar 

  • Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2006) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI 571: diverse mechanisms of resistance. Blood 96:1070–1079

    Google Scholar 

  • Oostendorp RL, Beijnen JH, Schellens JH, Tellingen O (2007) Determination of imatinib and its main metabolita in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomed Chromatogr 21:747–754

    Article  PubMed  CAS  Google Scholar 

  • Papac DI, Shahrokh Z (2001) Mass spectrometry innovations in drug discovery and development. Pharm Res 18:131–145

    Article  PubMed  CAS  Google Scholar 

  • Pen B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935–942

    Article  Google Scholar 

  • Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894

    Article  PubMed  CAS  Google Scholar 

  • Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496–3499

    Article  PubMed  CAS  Google Scholar 

  • Pirro E et al (2011) A new HPLC–UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. J Chromatogr Sci 49:753–757

    Article  PubMed  CAS  Google Scholar 

  • Roth O, Spreux-Varoquaux O, Bouchet S, Rousselot P, Castaigne S, Rigaudeau S, Raggueneau V, Therod P, Devillier P, Molimard M, Maneglier B (2010) Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC–MS/MS. Clin Chim Acta 411:140–146

    Article  PubMed  CAS  Google Scholar 

  • Savage DG, Antman KH (2002) Imatinib mesylate: a new oral targeted therapy. N Engl J Med 346:683–693

    Article  PubMed  CAS  Google Scholar 

  • Tomer KB (2001) Separations combined with mass spectrometry. Chem Rev 101:297–328

    Article  PubMed  CAS  Google Scholar 

  • Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diáz MG, Malec M, Langerak AW, San Miguel JF, Biondi A (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13:1901–1928

    Article  PubMed  Google Scholar 

  • Walz C, Sattler M (2006) Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57:145–164

    Article  PubMed  Google Scholar 

  • Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fondazione SDN, IRCSS, 80143, Naples, Italy

    Marianna Caterino

  2. CEINGE Biotecnologie Avanzate s.c.a r.l., 80131, Naples, Italy

    Giada Muccioli Casadei, Raffaele Arvonio, Fabrizio Pane & Margherita Ruoppolo

  3. Dipartimento di Biochimica e Biotecnologie Mediche, Università degli Studi di Napoli “FedericoII”, 80131, Naples, Italy

    Raffaele Arvonio, Fabrizio Pane & Margherita Ruoppolo

  4. Laboratorio di Farmacologia Clinica, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, AOU San Luigi Gonzaga, 10043, Orbassano, Italy

    Silvia De Francia, Elisa Pirro & Francesca Maria Piccione

Authors
  1. Marianna Caterino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giada Muccioli Casadei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaele Arvonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia De Francia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elisa Pirro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesca Maria Piccione
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabrizio Pane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Margherita Ruoppolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margherita Ruoppolo.

Additional information

This paper is dedicated to the memory of our much loved and missed colleague and friend Francesca Catanzano, who died prematurely.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 2074 kb)

Supplementary material 2 (TIFF 2907 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caterino, M., Casadei, G.M., Arvonio, R. et al. Quantification of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia: Comparison Between HPLC–UV and LC–MS/MS. Int J Pept Res Ther 19, 109–116 (2013). https://doi.org/10.1007/s10989-012-9321-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10989-012-9321-0

Keywords

Search

Navigation